Aclaris Therapeutics, Inc.
As of Oct 22, 2026, Aclaris Therapeutics is in Stage 3, the topping phase, now in week 3 (since Oct 5, 2026). It closed at $3.83, 41.4% below its 52-week high and below its 200-day average, which is rising.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ACRS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ACRS among Biotechnology79th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …79 | ACRS | Stage 3 · wk 3 | 89 | −27.2% |
Aclaris Therapeutics: quick answers
What stage is Aclaris Therapeutics in?
As of Oct 22, 2026, Aclaris Therapeutics (ACRS) is in Stage 3, the topping phase. It entered Stage 3 on Oct 5, 2026 and is in week 3. What the four stages mean
Is Aclaris Therapeutics in an uptrend?
Its uptrend has stalled. Aclaris Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 14.8% below its 200-day average, which is rising.
How far is Aclaris Therapeutics from its 52-week high?
Aclaris Therapeutics closed at $3.83 on Oct 22, 2026, 41.4% below its 52-week high of $6.54. Its 52-week low is $2.13.
How has Aclaris Therapeutics performed over the past year?
As of Oct 22, 2026, Aclaris Therapeutics is up 60.9% over the past year and up 33.0% so far in 2026.
Which sector and industry is Aclaris Therapeutics in?
Aclaris Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.